Abstract:Introduction FHND6091, a novel N-capped dipeptidyl boronic acid proteasome inhibitor with promising pharmacological properties, entirely converted into active form FHND6081 under physiological conditions. The proteasome, a key component of the ubiquitin-proteasome pathway (UPP), has emerged as a validated target of multiple myeloma (MM) therapeutics. FHND6091 is a selective oral proteasome inhibitor that binds irreversibly to the β5 submit of the 20S proteasome and exerts anti-cancer roles. Methods In this study, we investigated the metabolic stability, metabolite production, metabolic pathways and plasma protein binding (PPB) of FHND6081 along with its absorption, tissue distribution, excretion (ADME) and pharmacokinetics (PK) in animals. Results Ultra-high performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) identified a total of nine new metabolites after co-incubation with FHND6091 in hepatocytes from different species. A hypothetical CYP450-metabolic pathway including dehydrogenation, N-dealkylation plus mono-oxygenation and other was proposed. In addition, FHND6081 was highly bound to plasma proteins (>99%); nevertheless, it preferred to partition to red blood cells (B/P ratio: 4.91). The results of microsomal metabolic stability corroborated that FHND6081 was a moderate-clearance compound. In Caco-2 cell experiments, the compound displayed modest permeability suggesting that it may show limited bioavailability via oral routes. Furthermore, FHND6081 was extensively distributed in rats and the highest exposure was achieved in the stomach followed by the small intestine and adrenal gland. Pharmacokinetic studies were done by using Sprague-Dawley (SD) rats, oral absorption was fast and plasma exposure was dose-dependent and oral bioavailability were low. At the same dose, FHND6081 exposure was severalfold higher in whole blood than in plasma, which was consistent with blood cell partitioning. Moreover, only a small fraction of the parent compound was excreted via feces and urine and oxidative metabolites were detected in feces and plasma. Conclusion The overall preclinical pharmacokinetic profile supported the selection and development of FHND6091 as a clinical candidate.

Absorption, metabolism, and excretion of [<sup>14</sup>C]YY-20394, a highly selective PI3K-Delta inhibitor in humans

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Development and Validation of an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Quantitative Determination of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide in Dog Plasma

Preclinical metabolism and disposition of [14C]GFH009, a novel selective CDK9 inhibitor

Pharmacokinetics, Mass Balance, and Metabolism of [14C]PLB1004, a Selective and Irreversible EGFR-TKI in Humans

A mass balance study of [<SUP>14</SUP>C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

Mass balance study of [<SUP>14</SUP>C]SHR0302, a selective and potent JAK1 inhibitor in humans

Metabolism Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic Acid Hydroxyamide (CP-544439), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans

PRECLINICAL PHARMACOKINETIC ANALYSIS OF (E)-METHYL-4-ARYL-4-OXABUT-2-ENOATE, A NOVEL SER/THR PROTEIN KINASE B INIBITOR, IN RATS.

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

Study on Tissue Distribution, Metabolite Profiling, and Excretion of [14C]-Labeled Flonoltinib Maleate in Rats

Pharmacokinetics, Mass Balance and Metabolism of [14C]HSK21542, a Novel Kappa Opioid Receptor Agonist, in Humans

Sensitive Analysis and Pharmacokinetic Study of a Novel Gemcitabine Carbamate Prodrug and Its Active Metabolite Gemcitabine in Rats Using LC-ESI-MS/MS

Metabolism and Disposition of [14C]BMS-690514 ((3R,4R)-4-amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)methyl)-3-piperidinol), an ErbB/VEGFR Inhibitor, after Oral Administration to Humans

Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase

Absorption, Distribution, Metabolism, and Excretion of [<SUP>14</SUP>C]BS1801, a Selenium-Containing Drug Candidate, in Rats

Study on tissue distribution, metabolite profiling, and excretion of [ 14 C]-labeled flonoltinib maleate in rats

Metabolic Disposition of [14c]‐abivertinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: Role of Glutathione Conjugation

Evaluation of the pharmacokinetics, tissue distribution and excretion studies of YMR-65, a tubulin polymerization inhibitor with potential anticancer activity, in rats using UPLC-MS/MS.

Metabolism and Disposition of [14C]BMS-690514 after Oral Administration to Rats, Rabbits, and Dogs.

Preclinical Pharmacokinetics, Tissue Distribution and in Vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor